Thanks for your post Enumerate.
You wrote;
I am not 100% sure, but I think the diagnostic testing technology falls under the FDA Medical Devices regime. This is much lighter weight than full drug development. This means that Phylogica could take this to the market directly (and at a reduced cost and time).
I believe so too. It's a device so would have low regulatory hurdles.
Regards,
Tony
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.035(2.70%) |
Mkt cap ! $734.9M | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.31 | $1.26 | $2.681M | 2.075M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3081 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 700 | 1 |
View Market Depth
| Last trade - 16.11pm 28/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |